Drug
Treprostinil
Treprostinil: highest development phase Post-Market, developed by United Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| treprostinil sodium NCT00643604 | Post-Market | Hypertension, Pulmonary |
| Treprostinil NCT01268553 | Post-Market | Pulmonary Arterial Hypertension |
| treprostinil NCT00439946 | Post-Market | Pulmonary Arterial Hypertension |
| treprostinil sodium NCT01884038 | Phase 2/3 | Liver Transplant |
| oral treprostinil NCT02276872 | Phase 2 | PAH |
| Treprostinil NCT05564637 | Phase 2 | Pulmonary Arterial Hypertension |
| Treprostinil NCT00705133 | Phase 2 | Pulmonary Arterial Hypertension |
| oral treprostinil NCT02583789 | Phase 1 | Raynaud's Phenomenon |
Latest
No recent events.
Follow Treprostinil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.